Manuel Hidalgo
曼纽尔·伊达尔戈
MD, PhD
Chief, Hematology and Medical Oncology; Professor of Medicine血液学与内科肿瘤学主任；内科学教授
👥Biography 个人简介
Dr. Manuel Hidalgo is Chief of Hematology and Medical Oncology at Weill Cornell. He pioneered patient-derived xenograft (PDX) co-clinical trial platforms in PDAC, accelerating translation of novel therapies. He has led pivotal trials of nab-paclitaxel, KRAS-targeted agents, and combination immunotherapy in pancreatic cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PDX Co-Clinical Platforms
Established avatar PDX models from PDAC patients to predict individual drug responses in real time, enabling personalized therapy selection and validating biomarkers for clinical trial enrichment.
Nab-Paclitaxel Development
Co-led the MPACT phase III trial establishing nab-paclitaxel plus gemcitabine as first-line standard of care for metastatic PDAC, extending median overall survival and improving response rates.
Representative Works 代表性著作
MPACT: nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic PDAC
New England Journal of Medicine (2013)
Landmark phase III trial establishing nab-paclitaxel/gemcitabine as standard first-line therapy for metastatic PDAC.
Patient-derived xenografts predict clinical outcome in pancreatic cancer
Cancer Discovery (2021)
Validated PDX co-clinical trial approach for prospective therapy selection in PDAC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 曼纽尔·伊达尔戈 的研究动态
Follow Manuel Hidalgo's research updates
留下邮箱，当我们发布与 Manuel Hidalgo（Weill Cornell Medicine / NewYork-Presbyterian Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment